Wilson’s Disease

  • George J. Brewer
Part of the Current Clinical Neurology book series (CCNEU)


Patient 1: A 26-year-old man presented to a neurologist with a 6-month history of mild upper extremity tremor. He also felt that during the past year his memory was not as good as it used to be, and sometimes he had difficulty focusing mentally on tasks. Otherwise, the patient had been healthy. His family history revealed two ancestors on his mother’s side who had had mild tremor. Physical and neurological examinations were negative except for tremor. Laboratory studies were confined to blood counts and a biochemistry panel, which came back normal.


Essential Tremor Wilson Disease Menkes Disease Urine Copper Zinc Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912;34:295–509.CrossRefGoogle Scholar
  2. 2.
    Kayser B. Ueber einen Fall von angeborener grünlicher Verfärbung der kornea. Klin Mbl Augenheilk 1902;40:22–25.Google Scholar
  3. 3.
    Fleischer B. Zwei weitere Fälle von grünliche Verfärbung der Kornea. Klin Mbl Augenheilk 1903;41:489–491.Google Scholar
  4. 4.
    Glazebrook AJ. Wilson’s disease. Edinburgh Med J 1945;52:83–87.Google Scholar
  5. 5.
    Cumings JN. The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration. Brain 1948;71:410–415.PubMedCrossRefGoogle Scholar
  6. 6.
    Mandelbrote BM, Stanier MW, Thompson RHS, Thruston MN. Studies on copper metabolism in demyelinating disease of the central nervous system. Brain 1948;71:212–228.CrossRefPubMedGoogle Scholar
  7. 7.
    Ravestyn AH. Metabolism of copper in man. Acta Med Scand 1944;118:163–196.CrossRefGoogle Scholar
  8. 8.
    Frommer DJ. Defective biliary excretion of copper in Wilson’s disease. Gut 1974;15:125–129.PubMedCrossRefGoogle Scholar
  9. 9.
    Bearn AG, Kunkel HG. Biochemical abnormalities in Wilson’s disease. J Clin Invest 1952;31:616.Google Scholar
  10. 10.
    Scheinberg IH, Gitlin D. Deficiency of ceruloplasmin in patients with hepatolenticular degeneration (Wilson’s disease). Science 1952;116:484–485.PubMedCrossRefGoogle Scholar
  11. 11.
    Cumings JN. The effects of BAL in hepatolenticular degeneration. Brain 1951;74:10–22.PubMedCrossRefGoogle Scholar
  12. 12.
    Walshe JM. Penicillamine. A new oral therapy for Wilson’s disease. Am J Med 1956;21:487–495.PubMedCrossRefGoogle Scholar
  13. 13.
    Walshe JM. Treatment of Wilson’s disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1982;1:643–647.PubMedCrossRefGoogle Scholar
  14. 14.
    Schouwink G. De hepatocerebrale degeneratie, me een onderzoek naar de zinktofwisseling. University of Amsterdam: MD Thesis 1961.Google Scholar
  15. 15.
    Brewer GJ, Hill GM, Prasad AS, Cossack ZT, Rabbani P. Oral zinc therapy for Wilson’s disease. Ann Intern Med 1983;99:314–320.PubMedGoogle Scholar
  16. 16.
    Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JK. The Treatment of Wilson’s Disease with Zinc XV. Long-Term Follow-up Studies. J Lab Clin Med 1998;132:264–278.Google Scholar
  17. 17.
    Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Tanakow R, Young AB, Kluin KJ. Initial therapy of patients with Wilson’s disease with tetrathiomolybdate. Arch Neurol 1991;48:42–47.PubMedGoogle Scholar
  18. 18.
    Brewer GJ, Hedera P, Kluin KJ, et al. Treatment of Wilson’s disease with tetrathiomolybdate III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003;60:378–375.CrossRefGoogle Scholar
  19. 19.
    Bearn AG. A genetical analysis of thirty families with Wilson’s disease (hepatolenticular degeneration). Ann Hum Genet 1960;24:33–43.PubMedCrossRefGoogle Scholar
  20. 20.
    Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993;5:327–337.PubMedCrossRefGoogle Scholar
  21. 21.
    Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993;5:44–50.CrossRefGoogle Scholar
  22. 22.
    Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophy Res Commun 1993;197:271–277.CrossRefGoogle Scholar
  23. 23.
    Vulpe C, Levinson B, Whiney S, Packman S, Gitschier J. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATP-ase. Nat Genet 1993;3:7–13.PubMedCrossRefGoogle Scholar
  24. 24.
    Chelly J, Tumer Z, Tonnesen T, et al. Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. Nat Genet 1993;3:14–19.PubMedCrossRefGoogle Scholar
  25. 25.
    Mercer JF, Livingston J, Hall B, et al. Isolation of a partial candidate gene for Menkes disease by positional cloning. Nat Genet 1993;3:20–25.PubMedCrossRefGoogle Scholar
  26. 26.
    Cox DW, Roberts EA. Wilson disease. GeneClinics, University of Washington, Seattle. Online. Available:
  27. 27.
    Brewer GJ, Yuzbasiyan-Gurkan V. Wilson Disease. Medicine 1992;71:139–164.PubMedCrossRefGoogle Scholar
  28. 28.
    Scheinberg IH, Sternlieb I. Wilson’s Disease. In: Smith LH Jr, ed. Major Problems in Internal Medicine, vol. 23. W.B. Saunders Company, Philadelphia: 1984.Google Scholar
  29. 29.
    Brewer GJ. Recognition, diagnosis and management of Wilson’s disease. PSEBM 2000;223(1):39–49.CrossRefGoogle Scholar
  30. 30.
    Brewer, GJ. Wilson’s Disease: A Clinician’s Guide to Recognition, Diagnosis, and Management. Kluwer Academic, Boston: 2001.Google Scholar
  31. 31.
    Brewer GJ. Wilson’s Disease In: Kasper DL, Braunward E, Fauci AS, et al. eds. Harrison’s Principles of Internal Medicine. McGraw-Hill Companies, New York, 2004.Google Scholar
  32. 32.
    Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapy. Arch Neurol 1987;44:490–493.PubMedGoogle Scholar
  33. 33.
    Yuzbasiyan-Gurkan V, Grider A, Nostrant T, Cousins RJ, Brewer GJ. The treatment of Wilson’s disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 1992;120:380–386.PubMedGoogle Scholar
  34. 34.
    Askari FK, Greenson J, Dick RD, Johnson VD, Brewer GJ. Treatment of Wilson’s disease with Zinc XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 2003;142(6):385–390.PubMedCrossRefGoogle Scholar
  35. 35.
    Brewer GJ, Dick RD, Johnson V, et al. Treatment of Wilson’s disease with tetrathiomolybdate I. Initial therapy in 17 neurologically affected patients. Arch Neurol 1994;51:545–554.PubMedGoogle Scholar
  36. 36.
    Brewer GJ, Johnson V, Dick RD, Kluin KJ, Fink JK, Brunberg JA. Treatment of Wilson’s disease with ammonium tetrathiomolybdate: II. Initial therapy in 33 neurologically affected patients and follow-up on zinc therapy. Arch Neurol 1996;53:1017–1025.PubMedGoogle Scholar
  37. 37.
    Fink JK, Hedera P, Brewer GJ. Hepatolenticular degeneration (Wilson’s disease). Neurologist 1999;5:171–185.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2005

Authors and Affiliations

  • George J. Brewer
    • 1
  1. 1.Departments of Human Genetics and Internal MedicineUniversity of Michigan Medical SchoolAnn Arbor

Personalised recommendations